Evidence map›Paper›PMID 25997702›Full record

ArticleHuman cell2015

Slug contributes to gemcitabine resistance through epithelial-mesenchymal transition in CD133(+) pancreatic cancer cells.

Koichiro Tsukasa, Qiang Ding, Makoto Yoshimitsu, Yumi Miyazaki, Shyuichiro Matsubara, Sonshin Takao

Abstract read
PubMed Publisher
In one paragraph

Article in Human cell, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 40 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Curcumin: reclaiming the lost ground against cancer resistance.Cancer drug resistance (Alhambra, Calif.) · 2021
    Review
  11. Observational
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Predictable Resistance and Overall Survival of Gemcitabine/Cisplatin by Platelet Activation Index in Non-Small Cell Lung Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2018
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 2 countries.

Koichiro TsukasaDivision of Cancer and Regenerative Medicine, Frontier Biomedical Science and Swine Research Center, Kagoshima University, 8-35-1, Sakuragaoka, Kagoshima, 890-8520, Japan.
Qiang DingDivision of Cancer and Regenerative Medicine, Frontier Biomedical Science and Swine Research Center, Kagoshima University, 8-35-1, Sakuragaoka, Kagoshima, 890-8520, Japan.
Makoto YoshimitsuDepartment of Hematology and Immunology, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1, Sakuragaoka, Kagoshima, 890-8520, Japan.
Yumi MiyazakiDivision of Cancer and Regenerative Medicine, Frontier Biomedical Science and Swine Research Center, Kagoshima University, 8-35-1, Sakuragaoka, Kagoshima, 890-8520, Japan.
Shyuichiro MatsubaraDivision of Cancer and Regenerative Medicine, Frontier Biomedical Science and Swine Research Center, Kagoshima University, 8-35-1, Sakuragaoka, Kagoshima, 890-8520, Japan.
Sonshin TakaoDivision of Cancer and Regenerative Medicine, Frontier Biomedical Science and Swine Research Center, Kagoshima University, 8-35-1, Sakuragaoka, Kagoshima, 890-8520, Japan. sonshin@m2.kufm.kagoshima-u.ac.jp.
Kagoshima University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CD133-positive pancreatic cancer is correlated with unfavorable survival despite current development of therapy. Slug acts as a master regulator of epithelial-mesenchymal transition (EMT) which is the essential process in cancer progression. The aim of this study was to investigate the role of Slug in gemcitabine treatment for CD133-positive pancreatic cancer cells. We used a previously established pancreatic cancer cell line expressing high level of CD133 (Capan-1M9), which also expresses high level of Slug. We generated Slug knock-down subclone (shSlug M9) from this cell line, and compared expression of EMT-related genes, migration, invasion and gemcitabine resistance between two cell lines. Slug knock-down in CD133-positive pancreatic cancer cell line led to the reduction of migration and invasion ability. Furthermore, Slug knock-down sensitized CD133-positive pancreatic cancer cell line to gemcitabine. These results suggest that Slug plays an important role in not only invasion ability through EMT but also gemcitabine resistance of CD133-positive pancreatic cancer cells.

Indexed as

AC133 AntigenAntigens, CDAntimetabolites, AntineoplasticCell Line, TumorDeoxycytidineDrug Resistance, NeoplasmEpithelial-Mesenchymal TransitionGemcitabineGlycoproteinsHumansNeoplasm InvasivenessPancreatic NeoplasmsPeptidesSnail Family Transcription FactorsTranscription FactorsAC133 AntigenAntigens, CDAntimetabolites, AntineoplasticDeoxycytidineGemcitabineGlycoproteinsPeptidesPROM1 protein, humanSNAI1 protein, humanSnail Family Transcription FactorsTranscription FactorsCD133ChemoresistanceGemcitabinePancreatic cancerSlug

Identifiers

PMID25997702
OpenAlexW288228384

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.